OOIR: Observatory of International Research

Papers

(The TQCC of Biomarker Research is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Roles of IFN-γ in tumor progression and regression: a review	522
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors	262
Metabolic reprogramming in macrophage responses	213
Biomarkers for cancer-associated fibroblasts	140
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives	119
A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)	106
miR-21: a non‐specific biomarker of all maladies	105
Recent advances in systemic therapy for hepatocellular carcinoma	93
The landscape of bispecific T cell engager in cancer treatment	89
Targeting ferroptosis in breast cancer	86
Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer	71
CAR-NK cells for cancer immunotherapy: from bench to bedside	68
Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study	66
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study	64
A comprehensive comparison between camelid nanobodies and single chain variable fragments	64
Novel insights on targeting ferroptosis in cancer therapy	62
Imaging biomarkers for evaluating tumor response: RECIST and beyond	61
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	61
Role of platelet biomarkers in inflammatory response	61
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	56
Immunotherapy in endometrial cancer: rationale, practice and perspectives	52
Nanobody-based CAR-T cells for cancer immunotherapy	51
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues	50
Alternative Polyadenylation: a new frontier in post transcriptional regulation	48
The role of estrogen receptor beta in breast cancer	47

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies	47
Role of DNA repair defects in predicting immunotherapy response	47
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma	46
The biological function and clinical significance of SF3B1 mutations in cancer	46
Cancer-associated adipocytes as immunomodulators in cancer	45
Prolonged elevation of serum neurofilament light after concussion in male Australian football players	44
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth	43
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	43
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	43
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	41
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment	40
Advances in targeted therapy for acute myeloid leukemia	40
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	40
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis	40
The role of ferroptosis in lung cancer	40
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	38
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients	37
Targeting interleukin-1β and inflammation in lung cancer	37
Detection of circulating tumor cells: opportunities and challenges	35
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors	34
Risk factors for immune-related adverse events: what have we learned and what lies ahead?	34
TOX as a potential target for immunotherapy in lymphocytic malignancies	33
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment	33
Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia	33
The role of phosphatidylserine on the membrane in immunity and blood coagulation	32
Application of pharmacogenetics in oncology	32
Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function	31
Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions	31
Current views on the genetic landscape and management of variant acute promyelocytic leukemia	30
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	30
The emerging roles of N6-methyladenosine RNA methylation in human cancers	30
Metastasis-associated fibroblasts: an emerging target for metastatic cancer	29
The role of biomarkers in personalized immunotherapy	29
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	29
E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors	29
A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data	28
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	28
Targeting neoantigens for cancer immunotherapy	27
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies	27
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy	27
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer	26
N6-methyladenine modification in noncoding RNAs and its function in cancer	25
Intratumor microbiome in cancer progression: current developments, challenges and future trends	25
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?	23
Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance	23
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma	23
LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers	23
Recent updates on Sintilimab in solid tumor immunotherapy	23
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy	22
The emerging landscape of circular RNAs in immunity: breakthroughs and challenges	22

Biomarkers in individualized management of chimeric antigen receptor T cell therapy	22
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report	22
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer	22
The emerging role of RNA N6-methyladenosine methylation in breast cancer	22
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma	22
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma	22
Advances in the DNA methylation hydroxylase TET1	21
Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment	20
The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications	20
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma	20
Nucleases as molecular targets for cancer diagnosis	20
Current challenges and best practices for cell-free long RNA biomarker discovery	20
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma	20
The landscape overview of CD47-based immunotherapy for hematological malignancies	20
Detection and clinical significance of circulating tumor cells in colorectal cancer	20
Advances of cancer-associated fibroblasts in liver cancer	20
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	19
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse	19
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age	18
The intriguing roles of Siglec family members in the tumor microenvironment	18
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia	18
Epigenetic based synthetic lethal strategies in human cancers	18
Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy	18
Novel strategies for immuno-oncology breakthroughs with cell therapy	18